Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
by Sanghamitra Saha
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Eli Lilly (LLY) and U.S. Bancorp (USB).
Is Alexion (ALXN) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Alexion (ALXN).
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
by Zacks Equity Research
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
Economic & Earnings Data Deluge
by Zacks Equity Research
Economic & Earnings Data Deluge
Q4 Earnings Soldier on Gamely: GOOGL, CLX & More
by Mark Vickery
Eearnings reports to this point, based on strong consumer confidence and historically robust employment data (see Friday's 300K+ new jobs created last month), have been surprisingly positive amid these various and unpredictable headwinds.
Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alexion beat both earnings and sales estimates in the fourth quarter of 2018.
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
by Zacks Equity Research
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
4 Biotechs That Are Potential Buyouts Post Celgene Deal
by Ekta Bagri
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
by Zacks Equity Research
Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.
Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
by Zacks Equity Research
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
by Zacks Equity Research
Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.
Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
by Zacks Equity Research
Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.
Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
by Zacks Equity Research
Allakos (ALLK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Alexion Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Alexion Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
by Zacks Equity Research
Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.
Achillion Reports Positive Interim Data on Factor D Inhibitors
by Zacks Equity Research
Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.
AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
by Zacks Equity Research
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019
by Ekta Bagri
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Clovis Oncology (CLVS) shares rose nearly 7% in the last trading session, amid huge volumes.
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
by Kinjel Shah
Here are five stocks that are attractive and most likely to be takeout targets in 2019.